UA106225C2 - СОЛИ ПРОИЗВОДНЫХ ТЕТРАГИДРОИМИДАЗО[1,5-а]ПИРАЗИНА, СПОСОБ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ - Google Patents

СОЛИ ПРОИЗВОДНЫХ ТЕТРАГИДРОИМИДАЗО[1,5-а]ПИРАЗИНА, СПОСОБ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ

Info

Publication number
UA106225C2
UA106225C2 UAA201110708A UAA201110708A UA106225C2 UA 106225 C2 UA106225 C2 UA 106225C2 UA A201110708 A UAA201110708 A UA A201110708A UA A201110708 A UAA201110708 A UA A201110708A UA 106225 C2 UA106225 C2 UA 106225C2
Authority
UA
Ukraine
Prior art keywords
preparation methods
imidazo
tetrahydro
pyrazine derivatives
medicinal use
Prior art date
Application number
UAA201110708A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Inventor
Пенг Чо Танг
Пиаоянг Сун
Фанглонг Янг
Джиндонг Лианг
Гуангюан Шен
Янг Ванг
Джянг Фан
Original Assignee
Джянгсу Хенгруй Медисин Ко., Лтд.
Шанхай Хенгруй Фармасьютикал Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джянгсу Хенгруй Медисин Ко., Лтд., Шанхай Хенгруй Фармасьютикал Ко., Лтд. filed Critical Джянгсу Хенгруй Медисин Ко., Лтд.
Publication of UA106225C2 publication Critical patent/UA106225C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
UAA201110708A 2009-03-05 2010-03-03 СОЛИ ПРОИЗВОДНЫХ ТЕТРАГИДРОИМИДАЗО[1,5-а]ПИРАЗИНА, СПОСОБ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ UA106225C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN200910047075A CN101824036A (zh) 2009-03-05 2009-03-05 四氢咪唑并[1，5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
PCT/CN2010/000257 WO2010099698A1 (zh) 2009-03-05 2010-03-03 四氢咪唑并[1,5-a]吡嗪衍生物的盐，其制备方法及其在医药上的应用

Publications (1)

Publication Number Publication Date
UA106225C2 true UA106225C2 (ru) 2014-08-11

Family

ID=42688223

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201110708A UA106225C2 (ru) 2009-03-05 2010-03-03 СОЛИ ПРОИЗВОДНЫХ ТЕТРАГИДРОИМИДАЗО[1,5-а]ПИРАЗИНА, СПОСОБ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ

Country Status (12)

Country Link
US (1) US8518946B2 (https=)
EP (1) EP2404921B1 (https=)
JP (1) JP5976322B2 (https=)
KR (1) KR101731602B1 (https=)
CN (2) CN101824036A (https=)
AU (1) AU2010220722B2 (https=)
CA (1) CA2753862C (https=)
MX (1) MX2011009190A (https=)
RU (1) RU2523543C2 (https=)
UA (1) UA106225C2 (https=)
WO (1) WO2010099698A1 (https=)
ZA (1) ZA201107284B (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101899048B (zh) * 2009-05-27 2013-04-17 上海恒瑞医药有限公司 (R)-7-[3-氨基-4-(2,4,5-三氟-苯基)-丁酰]-3-三氟甲基-5,6,7,8-四氢-咪唑并[1,5-a]吡嗪-1-羧酸甲酯的盐
CN103724352B (zh) * 2012-10-16 2017-11-28 江苏盛迪医药有限公司 一种dpp‑iv抑制剂的中间体、其制备方法和通过其制备dpp‑iv抑制剂的方法
CN103664962A (zh) * 2013-12-20 2014-03-26 南京华威医药科技开发有限公司 哌嗪类衍生物
CN103910734B (zh) * 2014-03-28 2016-01-13 南京华威医药科技开发有限公司 一种具有哌嗪结构的dpp-4抑制剂
US10189841B2 (en) 2015-11-20 2019-01-29 Forma Therapeutics, Inc. Purinones as ubiquitin-specific protease 1 inhibitors
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
SG11202002877RA (en) 2017-10-31 2020-04-29 Hoffmann La Roche Bicyclic sulfones and sulfoxides and methods of use thereof
JP7553450B2 (ja) * 2018-12-28 2024-09-18 フォーマ セラピューティクス，インコーポレイテッド ユビキチン特異的プロテアーゼ１を阻害するための組成物
CN113620957B (zh) * 2020-05-08 2022-04-19 盛世泰科生物医药技术(苏州)有限公司 一种胺甲基吡嗪类化合物的制备方法
CN113773323B (zh) * 2020-06-10 2023-05-12 江苏恒瑞医药股份有限公司 3r-氨基取代丁酰胺衍生物的制备方法
CN113880825B (zh) * 2020-07-01 2025-03-14 浙江海正药业股份有限公司 四氢异喹啉类衍生物的盐、其制备方法及其医药应用
JP2024504328A (ja) * 2021-01-21 2024-01-31 ザ スクリプス リサーチ インスティテュート 肺疾患の治療のための肺胞２型細胞増殖の小分子調節因子
CN114057751B (zh) * 2022-01-17 2022-04-12 盛世泰科生物医药技术(苏州)有限公司 一种dpp-iv抑制剂及其关键中间体的制备方法
CN115583935A (zh) * 2022-11-03 2023-01-10 浙江工业大学 一种4-(2,4,5-三氟苯基)-3-氧丁酸酯的制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW492957B (en) 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
FR2780974B1 (fr) * 1998-07-08 2001-09-28 Sod Conseils Rech Applic Utilisation de derives d'imidazopyrazines pour preparer un medicament destine a traiter les pathologies qui resultent de la formation de la proteine g heterotrimetrique
US6110949A (en) 1999-06-24 2000-08-29 Novartis Ag N-(substituted glycyl)-4-cyanothiazolidines, pharmaceutical compositions containing them and their use in inhibiting dipeptidyl peptidase-IV
UA74912C2 (en) * 2001-07-06 2006-02-15 Merck & Co Inc Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
CN101468988A (zh) * 2007-12-26 2009-07-01 上海恒瑞医药有限公司 哌嗪类衍生物,其制备方法及其在医药上的应用

Also Published As

Publication number Publication date
KR101731602B1 (ko) 2017-04-28
CA2753862A1 (en) 2010-09-10
JP2012519193A (ja) 2012-08-23
WO2010099698A1 (zh) 2010-09-10
CN101824036A (zh) 2010-09-08
US20120065209A1 (en) 2012-03-15
CA2753862C (en) 2017-05-23
EP2404921A1 (en) 2012-01-11
HK1154574A1 (en) 2012-04-27
MX2011009190A (es) 2011-09-26
EP2404921A4 (en) 2012-08-15
CN102159578B (zh) 2013-04-10
ZA201107284B (en) 2012-12-27
JP5976322B2 (ja) 2016-08-23
AU2010220722B2 (en) 2015-05-07
AU2010220722A1 (en) 2011-10-27
RU2011137858A (ru) 2013-04-10
KR20110132561A (ko) 2011-12-08
CN102159578A (zh) 2011-08-17
EP2404921B1 (en) 2017-11-22
RU2523543C2 (ru) 2014-07-20
AU2010220722A2 (en) 2011-11-03
US8518946B2 (en) 2013-08-27

Similar Documents

Publication Publication Date Title
UA106225C2 (ru) СОЛИ ПРОИЗВОДНЫХ ТЕТРАГИДРОИМИДАЗО[1,5-а]ПИРАЗИНА, СПОСОБ ПОЛУЧЕНИЯ (ВАРИАНТЫ) И ИХ МЕДИЦИНСКОЕ ПРИМЕНЕНИЕ
MX2010006438A (es) Derivados de tetrahidro-imidazo [1,5-a] pirazina proceso de preparacion y su uso medicinal.
IL219424A (en) Imidazo derivative [b – 1,2] pyridazine, combinations, distant preparations containing them and process for their preparation and use as pde10 inhibitors
PH12013500742A1 (en) Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors
IL227087A0 (en) (2s,5r)-6-(benzyloxy/allyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylates, process for their preparation and use of (2s,5r)-tert-butyl-6 -(benzyloxy)-7-oxo-6,1-diazabicyclo[1.2.3]octane-2-carboxylate for the preparation of an anti-infective drug
TN2011000247A1 (en) Organic compounds
IL198314A (en) History of Quinuclidine of (hetero) Acrylic Cyclohepethecarboxylic Acid, Process of Preparation, Medicinal Preparations Containing Them and Use of Drug Preparation for Treatment
NZ601754A (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
WO2009071480A3 (en) Substituted dihydropteridin-6-one derivatives, process for their preparation and their use as kinase inhibitors
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
NZ630457A (en) Compounds useful as inhibitors of atr kinase
MX2009006613A (es) Derivados de pirazolo-quinazolina sustituidos, proceso para su preparacion y su uso como inhibidores de cinasa.
WO2009121945A3 (en) Dpp-iv inhibitor combined with a further antidiabetic agent, tablets comprising such formulations, their use and process for their preparation
IL211693A (en) Annotations3 –– Cyano – 6– (Amino Converted) –8– (Optionally Converted Amino) –Imidazo [2,1– b] Pyridazine and Pharmaceuticals Containing Them
MX2010009163A (es) Derivados heterociclicos de urea y metodos de uso de los mismos-211.
ZA201100429B (en) Novel imidazo [1,2-a]pyrimidine derivatives,method for the preparation thereof,use thereof as medicaments,pharmaceutical compositions and novel use in particular as met inhibitors
WO2010038081A3 (en) 4-amino-5- (hetero) aryl-2-phenylamino-pyrimidine or pyridine and their use as dna gyrase and/or topoisomerase iv inhibitors
MY160305A (en) Imidazo [1,2-a] pyrazine derivatives and their use for the prevention or treatment of neurological,psychiatric and metabolic disorders and diseases
WO2012030944A3 (en) Quinoline and isoquinoline derivatives for use as jak modulators
IL219371A (en) Ethylene History - (s-Triazolo / Pyrzolo) [a – 5,1] (Pyridine / Pyrimidine) and Pharmaceuticals Containing Them
UA106445C2 (ru) ГИДРАТ 1-{(2S)-2-АМИНО-4-[2,4-BIS(ТРИФТОРМЕТИЛ)-5,8-ДИГИДРОПИРИДО[3,4-d]ПИРИМИДИН-7(6H)-ИЛ]-4-ОКСОБУТИЛ}-5,5-ДИФТОРПИПЕРИДИН-2-ОНТАРТРАТА
IL210708A0 (en) Imidazo [1,2-a]pyrimidine derivatives method for the production thereof application thereof as medicaments pharmaceutical compositions and use thereof as met inhibitors
IL209270A (en) Compounds containing tricyclic nitrogen and their use as antibacterial
EP2549874A4 (en) SUBSTITUTED IMIDAZOLE [1,2-B] PYRIDAZINE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE AS BETA-SECRETASE INHIBITORS
IL217293A (en) Annotations of 9,8,7,6-tetrahydropyrimido {{a-2,1 pyramidine-4-one)